EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Acrivon Therapeutics's Enterprise Value is $-3.47 Mil.
Acrivon Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-63.77 Mil. Therefore, Acrivon Therapeutics's EV-to-FCF for today is 0.05.
The historical rank and industry rank for Acrivon Therapeutics's EV-to-FCF or its related term are showing as below:
ACRV'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.07 Med: 0 Max: 1.53
Current: 0.05
During the past 4 years, the highest EV-to-FCF of Acrivon Therapeutics was 1.53. The lowest was -5.07. And the median was 0.00.
ACRV's EV-to-FCF is ranked better than 92.91% of 395
companies
in the Biotechnology industry
Industry Median: 7.5
vs ACRV: 0.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Acrivon Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acrivon Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Acrivon Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrivon Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Acrivon Therapeutics's EV-to-FCF falls into.
Acrivon Therapeutics's current Enterprise Value is $-3.47 Mil.
Acrivon Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Acrivon Therapeutics's PE Ratio (TTM) for today is calculated as:
Acrivon Therapeutics's share price for today is $5.78.
Acrivon Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.710.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Acrivon Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Acrivon Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACRV has been successfully added to your 